logo
Doctors have figured out a way to use herpes to fight untreatable advanced cancer

Doctors have figured out a way to use herpes to fight untreatable advanced cancer

New York Post08-07-2025
Herpes has been called 'the gift that keeps on giving' — finally, its presence has come in handy.
Roughly two-thirds of the global population has been infected with herpes simplex virus type 1 (HSV-1), which typically causes painful and unsightly blisters around the mouth.
University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically modifying HSV-1 and administering it to patients with treatment-resistant, advanced skin cancer along with an anti-cancer medication.
4 About 3.8 billion people worldwide have been infected with herpes simplex virus type 1 (HSV-1), which typically causes painful and unsightly blisters around the mouth.
and.one – stock.adobe.com
In a recent clinical trial, this one-two punch shrank tumors by at least 30% in around one-third of the 140 participants. Nearly one in six saw their tumors completely disappear.
'These findings are very encouraging because melanoma is the fifth most common cancer for adults, and about half of all advanced melanoma cases cannot be managed with currently available immunotherapy treatments,' said Dr. Gino Kim In, a medical oncologist with Keck Medicine of USC.
Advanced melanoma means the skin cancer has spread from its initial location to other parts of the body, such as lymph nodes, the liver or the brain.
Immunotherapy to help the immune system attack cancer cells, targeted therapy and radiation therapy are common treatment options.
4 This is a close-up of the herpes virus, which may hold the key in the battle against advanced melanoma.
BSIP/Universal Images Group via Getty Images
'The survival rate of untreatable advanced melanoma is only a few years, so this new therapy offers hope to patients who may have run out of options to fight the cancer,' In said.
In January, the Food and Drug Administration granted priority review to RP1 (the genetically modified HSV-1) with the anti-cancer medication nivolumab (marketed as Opdivo) for advanced melanoma patients whose cancer had not responded to immunotherapy.
Nivolumab blocks a key protein that cancer cells use to evade the immune system, paving the way for the immune system to recognize and attack these cells.
The idea is that nivolumab would enhance the effects of RP1, which targets, infects and replicates in tumor cells to destroy them — while sparing healthy tissue.
In told The Post that RP1 was developed by knocking out specific genes in HSV-1 so that it no longer causes cold sores.
'Additional genetic modifications were made to the virus to stimulate the immune system to better fight the cancer and to help the virus more efficiently interact with and kill tumor cells,' In said.
4 Nivolumab blocks a key protein that cancer cells use to evade the immune system, paving the way for the immune system to recognize and attack these cells.
luchschenF – stock.adobe.com
In the USC trial, researchers injected RP1 into superficial tumors on or near the skin's surface and into tumors deeper in the body, like in the liver or lungs.
We're Tracking Prime Day Live!
Unlock exclusive NYP codes and real-time deals on everyday must-haves. See Your Deals
The combination therapy was administered every two weeks for up to eight cycles.
Afterwards, the patients who started to see results took just nivolumab every four weeks for up to two years.
Researchers were stunned to notice a difference in the size of the treated and untreated tumors. The untouched tumors shrank or disappeared as often as the injected ones.
'This result suggests that RPI is effective in targeting cancer throughout the entire body and not just the injected tumor,' said In, 'which expands the potential effectiveness of the drug because some tumors may be more difficult or impossible to reach.'
4 Dr. Gino Kim In, a medical oncologist with Keck Medicine of USC, is one of the lead investigators on the trial.
Keck Medicine of USC
RP1 was reported to be well-tolerated among the participants.
Results from the trial were published Tuesday in the Journal of Clinical Oncology and recently presented at the American Society of Clinical Oncology annual meeting.
In and his team launched a phase 3 trial to study the effects of this treatment in over 400 cancer patients.
People interested in participating in the trial, sponsored by RP1 manufacturer Replimune, should contact Sandy Tran at sandy.tran@med.usc.edu.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gym bros are taking these 'natural' injections to build muscle
Gym bros are taking these 'natural' injections to build muscle

Business Insider

time15 minutes ago

  • Business Insider

Gym bros are taking these 'natural' injections to build muscle

Hello! I'm Mia de Graaf. I run health coverage at Business Insider, and I'm stepping in for Joi-Marie this week while she's on vacation. Physically, I will be at home in New York City this summer. Mentally? Not so. This weekend, I am attempting to transport myself from my kitchen to Florence, Italy, with a zesty homemade agnolotti. Garlic, chiles, dill, and lime? Sign me up. On the agenda: Colonoscopies aren't fun. These new at-home colon cancer screenings offer a shortcut. Eight successful women in different industries told BI how they start their days. Here's one trick to escape huge crowds in Japan during peak season. Moms love this Yeti tote bag — and it's catching Wall Street's attention. But first: Let's check in on gym bros. If this was forwarded to you, sign up here. Download Business Insider's app here. This week's dispatch Hot peptide summer Earlier this week, I fell down a truly epic TikTok rabbit hole. It started with one video: a guy with cartoonish muscles bulging out of a tank top, sitting at his kitchen counter with six vials and a syringe. "It's time for me to get back in shape," he said. "So this is my new peptide stack." A whole hour later, I was deep in the bro wellness multiverse, where peptides rule. Peptides are short-chain amino acids, the building blocks of protein. In theory, you can use different peptides to stimulate different hormones for all kinds of results. You may have heard of peptide serums promising to boost collagen in your cheeks, or the weight-loss drug Ozempic, a peptide that suppresses hunger. Then, there are peptide shots that you can inject for muscle growth. The chiseled men on my phone screen told me that the idea is to "stack" various peptide shots because each one has slightly different effects. One may stimulate lean muscle, or melt fat for muscle definition, or heal your gym injuries, or slow aging. They rattled off laundry lists of technical names: BPC-157, CJC-1295, ipamorelin, follastatin 344, IGF-1… it goes on. There is a catch. As my colleague Hilary Brueck reports, the science behind muscle-building peptides is scant. Still, the trend is booming. Doctors say they are increasingly fielding questions from patients about which peptides they should use to retain muscle mass. The Vitamin Shoppe has seen a huge uptick in searches for peptides. Why? We're in our "natural gains" era. These days, quiet glow-ups are the hottest thing in cosmetic surgery. Similarly, drugs like steroids, which replace growth hormones, are seen as old-fashioned and toxic. Peptides stimulate your body's natural processes, so they're seen as more natural. This summer, beach bods are in — with a little help from a fridge full of syringes. Check your risk (at home) Colon cancer is the second-deadliest cancer in the US, in large part because people aren't getting their colon checked often enough. While colonoscopies are the most reliable tool, a new suite of at-home tests is rapidly expanding. One recently approved screening tool checks your blood for signs that something is awry. Another highly anticipated test, which isn't out yet, may require nothing more than your breath. Four colonoscopy alternatives. She wakes up like this There's no one-size-fits-all approach to optimizing your morning routine. However, there are a lot of options to try out and many recipes for success. BI spoke to eight successful women across different industries, from professional dancers to bankers and CEOs. Most said they wake up around 6 a.m., but their routines diverge from there. Some hit the gym, while others do affirmations. Also read: Seven men told us how they start their days. Fancy alarm clocks and morning runs are key to their success. Sakura season, without the crowds BI's Anneta Konstantinides visited Japan for its famed cherry blossom season in March, right as the country was experiencing record tourism. While the most popular attractions in Tokyo and Kyoto felt crowded, Konstantinides quickly figured out an easy, affordable, and crowd-free way to enjoy the sights in peak bloom. The secret was in Japan's gardens. The holy grail mom bag The Yeti Camino 35 Caryall Tote Bag has a chokehold on moms on TikTok. They tout it as the sleekest, most durable bag for carrying an array of items while also ferrying their children from place to place. It's even got Wall Street's attention. In a recent note, Jefferies analysts said the Camino 35's virality is boosting confidence in Yeti Holdings' stock. Check it out. What we're watching this weekend "Happy Gilmore 2": Nearly three decades after Adam Sandler's comedy about an unlikely golf hero hit theaters, the comedian's star-studded sequel is coming to Netflix. "The Phoenician Scheme": Wes Anderson's latest film, a surprisingly comedic crime caper starring Benicio del Toro, makes its streaming debut on Peacock. "Hitmakers": Netflix's new reality docuseries about the glamorously cutthroat world of professional songwriting is an entertaining peek behind the curtain at how some of your favorite pop songs get made. What to shop New Yorker must-haves: Discover editor Gabrielle Chase's guide to NYC essentials — packed with smart recommendations on what to pack, where to shop, and how to blend in like a local. One ring to track it all: We put the Oura Ring 4 to the test. It packs powerful health tracking into a sleek, screen-free design. It's discreet, durable, and lasts a week on a charge, but its high price keeps it in luxury territory. Small desk, big upgrade: This sit‑stand desk blends space‑saving design with effortless electric height adjustment — perfect for tight spaces. We tried it, and loved its customizable finishes, sleek design, and smart features. More of this week's top reads: The hidden dilemma of Ozempic: eating disorder recovery. Drew Brees says he's a "very common-sense dieter." Here are five simple wellness rules he lives by. Seven things you should never do when traveling by train, according to an etiquette coach. I've lived in the Hamptons for most of my life. Here are five mistakes I see visitors make every summer. The Coldplay "kiss cam" situation underlines a lesson I learned as a 15-year-old cheerleader. I went to a medical clinic in Portugal — thousands of miles from my NYC home. I saved $500 and found an answer for my back pain. I was born and raised in Italy. There are seven things I wish tourists would stop doing when they come here. The millennial case against having baby number three.

Serious liver disease is up among heavy drinkers, even without more drinking
Serious liver disease is up among heavy drinkers, even without more drinking

Los Angeles Times

time44 minutes ago

  • Los Angeles Times

Serious liver disease is up among heavy drinkers, even without more drinking

Serious liver disease is becoming more common among Americans who drink heavily, according to a new study from Keck Medicine of USC. It's not that more people are partying with alcohol. And it's not that the drinkers are having more drinks. It's that more of the people who drink regularly are becoming sick. Over the last two decades, the share of heavy drinkers who have advanced liver scarring jumped from 1.8% to 4.3%. For women, more than 1.5 drinks per night, on average, is considered heavy drinking. For men, it's 2 drinks. 'The fact that the risk not only increased but that it more than doubled — almost tripled — is really astonishing,' said Dr. Brian P. Lee, a liver transplant specialist at Keck Medicine of USC and lead author on the study. It was published in the journal Clinical Gastroenterology and Hepatology on Wednesday. Lee said he thinks patients might dramatically change their thinking and behavior if they had this information. The increase in illness was seen especially in women, older people and those with conditions like obesity or diabetes. Three USC researchers analyzed national health data from more than 44,000 adults surveyed between 1999 and 2020 in a well-known national heath study known as NHANES. Of those, 2,474 were heavy drinkers according to the definition of the National Institute on Alcohol Abuse and Alcoholism — 20 grams of alcohol per day for women and 30 grams for men, roughly the equivalent of 1.5 and 2 drinks. They found a more than twofold increase over the two decades in significant liver fibrosis, a condition where healthy liver tissue is replaced by stiff, fibrous tissue — like a sponge hardening into leather. If left unchecked, this can eventually lead to liver failure or cancer. By comparison, non-heavy drinkers saw a much smaller increase, from 0.8% to 1.4% over the same period. This rise in liver damage is especially troubling because many people don't realize anything is wrong until the disease is advanced. 'Liver disease is silent,' Lee said. 'Most people won't, even if they have [advanced liver scarring], have any symptoms at all.' Drinking patterns did not change much over the study period. But the health profiles of heavy drinkers did. Rates of metabolic syndrome — a cluster of conditions including obesity, diabetes, and high blood pressure — increased from 26% of people, to nearly 38%. Demographics shifted too: heavy drinkers became more likely to be women, people over the age of 45, and those living in poverty. 'We're showing with this study that the picture of the American drinker is changing dramatically,' Lee said. 'You have more women who are drinking heavily, more ethnic minorities who are drinking heavily, and these are groups that are known to have a higher sensitivity to alcohol in causing liver damage.' Other factors may also be at play, said Dr. Sammy Saab, medical director of the Pfleger Liver Institute at UCLA, who was not involved in the study. People could be consuming different types of drinks, or at different times. 'Have we moved away from beer, wine, to hard cocktails? Have we moved away from drinking with food, where the food absorbs some of the alcohol you consume, versus drinking without food where alcohol is better absorbed?' Saab asked. Then there are cultural changes, he said. 'In the old days, if you drank, you'd still have to drive home, but now we've got Uber, we have Lyft,' he said, which may remove some deterrents to heavy drinking. The current definition of heavy drinking in the U.S. may actually be too lenient, Lee said, especially compared to evolving global standards. Canada, for example, now advises no more than two drinks per week to minimize health risks. 'In the U.S. right now, we consider heavy drinking to be eight drinks or more per week for women and 15 or more for men — but that's quite high,' he said. 'We've shown in prior studies that you can develop liver disease at lower quantities than the U.S. threshold.' The study's findings highlight the need to rethink long-held assumptions about alcohol-related liver disease, and Lee hopes it can be used to develop more effective screening methods for early detection. The paper raises a lot of good questions, Saab said, serving as a call to action for researchers and clinicians to better understand this increase in alcohol-associated liver disease — and how to stop it.

Lawmakers press FDA to target knockoff weight-loss drug
Lawmakers press FDA to target knockoff weight-loss drug

Los Angeles Times

time12 hours ago

  • Los Angeles Times

Lawmakers press FDA to target knockoff weight-loss drug

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartis an lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. Muller writes for Bloomberg.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store